PharmaSGP Holding SE
XETRA:PSG
Intrinsic Value
PharmaSGP Holding SE engages in the sale and marketing of non-prescription drugs, chemical-free over-the-counter painkillers, as well as herbal medicines. [ Read More ]
The intrinsic value of one
PSG
stock under the Base Case scenario is
37.06
EUR.
Compared to the current market price of 22.2 EUR,
PharmaSGP Holding SE
is
Undervalued by 40%.
PharmaSGP Holding SE's market capitalization is 266.3m EUR.
PSG stock price is 22.2 EUR.
PSG stock price (22.2 EUR) is 40% less than its Intrinsic Value (37.06 EUR).
PSG has upside potential of 70% compared to the average analyst price target.
Open Wall St Estimates
PSG has positive Net Debt. This means that the company has more debt (74m EUR) than cash and short-term investments (38m EUR).
PSG's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 17%.
PSG's Revenue has grown by an exceptional 21% over the past 12 months.
PSG's Revenue is forecast to grow at a rate of 10% per year over the next 3 years.
PSG has positive Net Income for the last twelve months.
PSG's long-term assets (134m EUR) exceed its long-term liabilties (100m EUR).
PSG's Revenue has been growing by 12% per year for the last 3 years.
PSG has positive Operating Income for the last twelve months.
PSG's Altman Z-Score is equal to 2.99.
PSG's ROE (Return on Equity) has significantly increased in the last 3 years from 15% to 46%.
PSG's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 94% to 17%.
PSG generates enough operating income (20m EUR) to cover interest payments on its debt (2m EUR).
PSG's ROE (Return on Equity) for the past 12 months is very high and is equal to 46%.
PSG's D/E (Debt to Equity) is very high and is equal to 2.21.
PSG's short-term assets (59m EUR) exceed its short-term liabilties (25m EUR).
PSG has positive Gross Profit for the last twelve months.
PSG has positive Free Cash Flow for the last twelve months.
PSG has very high three-year average ROE (Return on Equity): 71%. The company is very efficient at transforming stockholders' equity into net income.
PSG has very high three-year average ROIC (Return on Invested Capital): 80%. The company is very efficient at using invested capital to generate operating income.
Valuation Backtest
PharmaSGP Holding SE
Run backtest to discover the historical profit from buying and selling
PSG
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
PharmaSGP Holding SE
Balance Sheet Decomposition
PharmaSGP Holding SE
| Current Assets | 58.5m |
| Cash & Short-Term Investments | 38.3m |
| Receivables | 9.2m |
| Other Current Assets | 11m |
| Non-Current Assets | 75m |
| Long-Term Investments | 1.7m |
| PP&E | 1.5m |
| Intangibles | 71.9m |
| Current Liabilities | 25m |
| Accounts Payable | 12.2m |
| Other Current Liabilities | 12.9m |
| Non-Current Liabilities | 75.1m |
| Long-Term Debt | 73.9m |
| Other Non-Current Liabilities | 1.3m |
Earnings Waterfall
PharmaSGP Holding SE
|
Revenue
|
89.3m
EUR
|
|
Cost of Revenue
|
-8.9m
EUR
|
|
Gross Profit
|
80.4m
EUR
|
|
Operating Expenses
|
-60.6m
EUR
|
|
Operating Income
|
19.7m
EUR
|
|
Other Expenses
|
-6.6m
EUR
|
|
Net Income
|
13.1m
EUR
|
Free Cash Flow Analysis
PharmaSGP Holding SE
PSG Profitability Score
Profitability Due Diligence
PharmaSGP Holding SE's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
Score
PharmaSGP Holding SE's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
PSG Solvency Score
Solvency Due Diligence
PharmaSGP Holding SE's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
PharmaSGP Holding SE's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PSG Price Targets Summary
PharmaSGP Holding SE
According to Wall Street analysts, the average 1-year price target for
PSG
is 37.74 EUR
with a low forecast of 36.36 EUR and a high forecast of 39.9 EUR.
Shareholder Return
PSG Price
PharmaSGP Holding SE
| Average Annual Return | -6.77% |
| Standard Deviation of Annual Returns | 11.48% |
| Max Drawdown | -53% |
| Market Capitalization | 266.3m EUR |
| Shares Outstanding | 11 990 200 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
PharmaSGP Holding SE
Country
Industry
Market Cap
Dividend Yield
Description
PharmaSGP Holding SE engages in the sale and marketing of non-prescription drugs, chemical-free over-the-counter painkillers, as well as herbal medicines. The company is headquartered in Graefelfing, Bayern. The company went IPO on 2020-06-19. The firm produces and develops non-chemical and over-the-counter drugs and other healthcare products.
Contact
IPO
Employees
Officers
The intrinsic value of one
PSG
stock under the Base Case scenario is
37.06
EUR.
Compared to the current market price of 22.2 EUR,
PharmaSGP Holding SE
is
Undervalued by 40%.
You don't have any saved screeners yet
